AU2004220459B2 - Polypeptide compounds for inhibiting angiogenesis and tumor growth - Google Patents

Polypeptide compounds for inhibiting angiogenesis and tumor growth Download PDF

Info

Publication number
AU2004220459B2
AU2004220459B2 AU2004220459A AU2004220459A AU2004220459B2 AU 2004220459 B2 AU2004220459 B2 AU 2004220459B2 AU 2004220459 A AU2004220459 A AU 2004220459A AU 2004220459 A AU2004220459 A AU 2004220459A AU 2004220459 B2 AU2004220459 B2 AU 2004220459B2
Authority
AU
Australia
Prior art keywords
polypeptide
ephb4
ephrin
soluble
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004220459A
Other languages
English (en)
Other versions
AU2004220459A1 (en
Inventor
Parkash Gill
Nathalie Kertesz
Valery Krasnoperov
Ramachandra Reddy
Sergey Zozulya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vasgene Therapeutics Inc
Original Assignee
Vasgene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vasgene Therapeutics Inc filed Critical Vasgene Therapeutics Inc
Publication of AU2004220459A1 publication Critical patent/AU2004220459A1/en
Application granted granted Critical
Publication of AU2004220459B2 publication Critical patent/AU2004220459B2/en
Priority to AU2010238577A priority Critical patent/AU2010238577B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
AU2004220459A 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth Ceased AU2004220459B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2010238577A AU2010238577B2 (en) 2003-03-12 2010-11-01 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US45443203P 2003-03-12 2003-03-12
US45430003P 2003-03-12 2003-03-12
US60/454,432 2003-03-12
US60/454,300 2003-03-12
PCT/US2004/007755 WO2004080425A2 (en) 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2010238577A Division AU2010238577B2 (en) 2003-03-12 2010-11-01 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Publications (2)

Publication Number Publication Date
AU2004220459A1 AU2004220459A1 (en) 2004-09-23
AU2004220459B2 true AU2004220459B2 (en) 2010-08-05

Family

ID=32994555

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2004220459A Ceased AU2004220459B2 (en) 2003-03-12 2004-03-12 Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2004220525A Ceased AU2004220525B2 (en) 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
AU2010238577A Ceased AU2010238577B2 (en) 2003-03-12 2010-11-01 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2004220525A Ceased AU2004220525B2 (en) 2003-03-12 2004-03-12 Nucleic acid compounds for inhibiting angiogenesis and tumor growth
AU2010238577A Ceased AU2010238577B2 (en) 2003-03-12 2010-11-01 Polypeptide compounds for inhibiting angiogenesis and tumor growth

Country Status (6)

Country Link
US (5) US7585967B2 (https=)
EP (2) EP1606305A4 (https=)
JP (3) JP2006521111A (https=)
AU (3) AU2004220459B2 (https=)
CA (2) CA2518898A1 (https=)
WO (2) WO2004080418A2 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887674B1 (en) 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
AU2002951409A0 (en) * 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
AU2003268345A1 (en) 2002-09-24 2004-04-19 The Burnham Institute Novel agents that modulate eph receptor activity
EP1606305A4 (en) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
US7381410B2 (en) 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DK1730196T3 (da) 2004-03-12 2011-03-28 Vasgene Therapeutics Inc EphB4-bindende antistoffer til inhibering af antiogenese og tumorvækst
CN101072797B (zh) * 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
JP2007320850A (ja) * 2004-08-24 2007-12-13 Kyowa Hakko Kogyo Co Ltd 抗エフリンｂ２抗体
AU2005286663A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Compositions and methods for detecting and treating tumors
CA2581423A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
DE102004054016A1 (de) * 2004-11-09 2006-05-11 Robert Bosch Gmbh Steuergerät zum Steuern und/oder regeln mindestens einer Fahrzeugfunktion
ES2556272T3 (es) * 2004-11-18 2016-01-14 The Board Of Trustees Of The University Of Illinois Constructos de ARNsi multicistrónico para inhibir tumores
CA2593325A1 (en) * 2005-01-06 2006-07-13 Genentech, Inc. Cancer prognostic, diagnostic and treatment methods
JP2008528614A (ja) * 2005-01-27 2008-07-31 ザ・バーンハム・インスティテュート ＥｐｈＢ受容体結合ペプチド
FR2889200B1 (fr) 2005-07-27 2008-01-04 Inst Vaisseaux Et Du Sang Ass Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
US20070218061A1 (en) * 2005-09-23 2007-09-20 Vasgene Therapeutics, Inc. Use of ephrinb2 directed agents for the treatment or prevention of viral infections
SI1976884T1 (sl) 2006-01-20 2013-04-30 Genetech, Inc. Anti-efrinB2 protitelesa in postopki uporabe le teh
ES2911034T3 (es) 2006-08-08 2022-05-17 Univ Bonn Rheinische Friedrich Wilhelms Estructura y uso de oligonucleótidos 5' fosfato
US20110052667A1 (en) * 2007-06-28 2011-03-03 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
CA2696164C (en) 2007-08-13 2018-06-12 Vasgene Therapeutics, Inc. Cancer treatment using humanized antibodies that bind to ephb4
US8357501B2 (en) 2007-11-29 2013-01-22 Molecular Health Gmbh Tissue protective erythropoietin receptor (NEPOR) and methods of use
ES2386495T3 (es) * 2007-11-29 2012-08-21 Molecular Health Gmbh siARN específico de EPH-B4 para reducir el crecimiento de células neoplásicas inducidas por EPO durante el tratamiento de anemia en pacientes con cáncer, receptor de eritropoyetina protector de tejido (NEPOR) y métodos de uso
WO2009141146A1 (en) 2008-05-21 2009-11-26 Gunther Hartmann 5' triphosphate oligonucleotide with blunt end and uses thereof
WO2012112434A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
EP2508530A1 (en) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Purification of triphosphorylated oligonucleotides using capture tags
EP2712870A1 (en) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Novel RIG-I ligands and methods for producing them
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
US20190343880A1 (en) * 2016-12-14 2019-11-14 Shinshu University Chimeric antigen receptor gene-modified lymphocyte having cytocidal effect
WO2020146723A1 (en) * 2019-01-10 2020-07-16 Massachusetts Institute Of Technology Functional analysis of cancer cells
US12560590B2 (en) 2019-01-23 2026-02-24 Massachusetts Institute Of Technology Rapid analysis of live cells
CA3181420A1 (en) * 2020-05-28 2021-12-02 Cytobay Inc. Cytopathological staining
EP4105328A1 (en) 2021-06-15 2022-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Antisense-oligonucleotides for prevention of kidney dysfunction promoted by endothelial dysfunction by ephrin-b2 suppression
JPWO2023224096A1 (https=) * 2022-05-18 2023-11-23

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5674691A (en) 1991-06-21 1997-10-07 Amrad Corporation Limited Method of screening for ligands to a receptor-type tyrosine kinase
US6331302B1 (en) * 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
AU3482493A (en) 1992-01-22 1993-09-01 New England Deaconess Hospital Novel protein tyrosine kinases
AU687727B2 (en) 1992-10-28 1998-03-05 Genentech Inc. Vascular endothelial cell growth factor antagonists
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
JPH08505765A (ja) 1992-11-13 1996-06-25 アムジエン・インコーポレーテツド Ｅｃｋ受容体リガンド
US5512591A (en) * 1993-02-18 1996-04-30 President And Fellows Of Harvard College Treatments for diseases characterized by neovascularization
ES2152753B1 (es) 1993-03-29 2001-09-01 Ct Investig Energeticas Ciemat Animales transgenicos para la determinacion de agentes que estimulan o reprimen la hiperproliferacion epidermica y el crecimiento del pelo
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6303769B1 (en) * 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
WO1996003043A1 (en) 1994-07-26 1996-02-08 Rutgers, The State University Of New Jersey Human brain specific kinase
US5795734A (en) 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
EP0787148B1 (en) 1994-10-27 2004-04-07 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
WO2002096927A2 (en) * 2001-05-29 2002-12-05 Ribozyme Pharmaceuticals, Incorporated Ribozyme based treatment of female reproductive diseases
US6346398B1 (en) * 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
US5837534A (en) * 1995-11-14 1998-11-17 The Board Of Regents Of The University Of Texas System Smooth muscle 22α promoter, gene transfer vectors containing the same, and method of use of the same to target gene expression in arterial smooth muscle cells
AUPN727795A0 (en) 1995-12-22 1996-01-18 Walter And Eliza Hall Institute Of Medical Research, The A novel receptor-type tyrosine kinase and use thereof
US6696557B1 (en) * 1996-04-19 2004-02-24 Genentech, Inc. AL-2 neurotrophic factor nucleic acid
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
CA2259157A1 (en) 1996-07-05 1998-01-15 Mount Sinai Hospital Corporation Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
KR100816621B1 (ko) 1997-04-07 2008-03-24 제넨테크, 인크. 항-ｖｅｇｆ 항체
AU6887698A (en) 1997-04-08 1998-10-30 Sugen, Inc. Study and treatment of diseases related to specific cellular functions of receptor protein tyrosine kinases
US6440954B1 (en) * 1997-04-18 2002-08-27 President And Fellows Of Harvard College Inhibition of vascular smooth muscle cell proliferation
WO1999008696A1 (en) 1997-08-19 1999-02-25 Vanderbilt University METHODS FOR DETERMINING CELL RESPONSES THROUGH EphB RECEPTORS
EP1019080A2 (en) * 1997-10-02 2000-07-19 Leukosite, Inc. Modulation of lerk-2-mediated cell adhesion
WO1999045026A1 (en) * 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6864227B1 (en) * 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
EP0999278B1 (en) 1998-10-02 2004-03-31 Universite Paris Vii Vascular specific regulatory elements contained in the desmin 5' flanking region
AUPP674898A0 (en) 1998-10-27 1998-11-19 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment
ATE293989T1 (de) * 1998-11-20 2005-05-15 Genentech Inc Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
US6150162A (en) * 1998-12-17 2000-11-21 Isis Pharmaceuticals Inc. Antisense modulation of CD44 expression
US6770633B1 (en) * 1999-10-26 2004-08-03 Immusol, Inc. Ribozyme therapy for the treatment of proliferative skin and eye diseases
CA2396114A1 (en) * 2000-01-06 2001-07-12 Andrew Freywald Methods of modulation of the immune system
JP2004509604A (ja) * 2000-03-28 2004-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド ｍＲＮＡプロセッシングのアンチセンスモジュレーションによる、細胞行動の改変
EP2213743A1 (en) * 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001257174A1 (en) 2000-04-21 2001-11-07 Amgen Inc. Integrin/adhesion antagonists
US6271030B1 (en) * 2000-06-14 2001-08-07 Isis Pharmaceuticals, Inc. Antisense inhibition of C/EBP beta expression
US6277640B1 (en) * 2000-07-31 2001-08-21 Isis Pharmaceuticals, Inc. Antisense modulation of Her-3 expression
EP1392333A2 (en) 2000-08-03 2004-03-03 The University of Utah Research Foundation Manipulation of arterial-venous identity
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US7136808B2 (en) * 2000-10-20 2006-11-14 Microsoft Corporation Detection and correction of errors in german grammatical case
IL156009A0 (en) * 2000-11-20 2003-12-23 California Inst Of Techn Artery smooth muscle and vein smooth muscle specific proteins and uses therefor
CA2429814C (en) * 2000-12-01 2014-02-18 Thomas Tuschl Rna interference mediating small rna molecules
AU2002243623A1 (en) 2001-01-26 2002-08-06 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
US20040132634A1 (en) 2001-01-31 2004-07-08 Frank Sicheri Compositions and methods for regulating the kinase domain of receptor tyrosine kinases
AU2002249170B2 (en) 2001-02-02 2007-02-08 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V Method for identifying functional nucleic acids
EP1383782A1 (en) * 2001-03-26 2004-01-28 Sirna Therpeutics, Inc. Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication
US6919313B2 (en) 2001-03-30 2005-07-19 President & Fellows Of Harvard College Protein waving a PDZ and a RGS domain
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
PT2000545E (pt) * 2001-06-20 2011-12-21 Genentech Inc Composições e métodos para o diagnóstico e tratamento do tumor pulmonar
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
WO2003004057A1 (en) * 2001-07-03 2003-01-16 The Hospital For Sick Children Ephrin and eph receptor mediated immune modulation
JP3876656B2 (ja) * 2001-07-13 2007-02-07 住友金属工業株式会社 管用ねじ継手
AU2002353972A1 (en) * 2001-11-02 2003-05-19 Pfizer Products Inc. Lung cancer therapeutics and diagnostics
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
JP4585968B2 (ja) 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
ATE525398T1 (de) 2002-05-10 2011-10-15 Medimmune Inc Epha2 monoklonale antikörper und deren anwendungsverfahren
US20040110150A1 (en) * 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
AU2003254641A1 (en) 2002-08-28 2004-03-19 Maxygen Aps Interferon beta-like molecules for treatment of cancer
AU2003260169B9 (en) * 2002-09-16 2011-06-09 The Queen Elizabeth Hospital Research Foundation Inc. Methods for regulating cancer
AU2002951409A0 (en) 2002-09-16 2002-09-26 North Western Adelaide Health Services Methods for regulating cancer
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US7250289B2 (en) * 2002-11-20 2007-07-31 Affymetrix, Inc. Methods of genetic analysis of mouse
EP1606305A4 (en) * 2003-03-12 2009-06-24 Vasgene Therapeutics Inc NUCLEIC ACID COMPOUNDS FOR THE INHIBITION OF ANGIOGENESIS AND TUMOR GROWTH
NZ567952A (en) * 2003-03-24 2009-12-24 Sequoia Pharmaceuticals Inc Long acting biologically active conjugates
WO2004091375A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Epha2 and non-neoplastic hyperproliferative cell disorders
EP1618184A4 (en) * 2003-04-11 2006-06-21 Medimmune Inc EPHA2, HYPOPROLIFERATIVE CELL DISORDERS, AND EPITHELIAL AND ENDOTHELIAL RECONSTITUTION
KR20060034231A (ko) 2003-06-06 2006-04-21 메디뮨 인코포레이티드 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도
WO2005037232A2 (en) * 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
EP1689346A4 (en) 2003-11-20 2007-11-21 Medimmune Inc EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHOD OF USE THEREOF
CN101072797B (zh) 2004-03-12 2012-05-09 瓦斯基因治疗公司 结合ephb4、抑制血管发生和肿瘤生长的抗体
CA2581423A1 (en) 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5624899A (en) * 1994-07-20 1997-04-29 Genentech Inc. Method for using Htk ligand

Also Published As

Publication number Publication date
CA2518898A1 (en) 2004-09-23
AU2010238577B2 (en) 2012-05-24
EP1606305A4 (en) 2009-06-24
AU2004220525A1 (en) 2004-09-23
US20050164965A1 (en) 2005-07-28
WO2004080425A2 (en) 2004-09-23
WO2004080418A3 (en) 2005-05-06
US8063183B2 (en) 2011-11-22
EP1605961A2 (en) 2005-12-21
JP2011256179A (ja) 2011-12-22
WO2004080425A3 (en) 2005-07-07
EP1606305A2 (en) 2005-12-21
JP4762889B2 (ja) 2011-08-31
AU2010238577A1 (en) 2010-11-18
JP2006519610A (ja) 2006-08-31
US20070031435A1 (en) 2007-02-08
US20110129482A1 (en) 2011-06-02
EP1605961A4 (en) 2009-11-11
JP2006521111A (ja) 2006-09-21
AU2004220525B2 (en) 2011-03-31
AU2004220459A1 (en) 2004-09-23
US7585967B2 (en) 2009-09-08
US20100093831A1 (en) 2010-04-15
WO2004080418A2 (en) 2004-09-23
US20050084873A1 (en) 2005-04-21
US7862816B2 (en) 2011-01-04
CA2518912A1 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
AU2010238577B2 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
US8273858B2 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
AU2005286662B2 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20110213127A1 (en) Methods for using and identifying modulators of delta-like 4
AU2007338734A1 (en) Methods for using and identifying modulators of delta-like 4
MX2012012735A (es) Deteccion y modulacion de formacion de vasos linfaticos mediados por la proteina slit y roundabount (robo), y usos de los mismos.

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE CO- INVENTOR FROM KERETESZ, NATHALIE TO KERTESZ, NATHALIE

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired